Clinical review for general practice

ISSN (Print) 2713-2552
ISSN (Online) 2782-5671
  • Home
  • about
  • archives
  • contacts
left
FULLSCREEN > Archive > 2025 > Vol 6, №6 (2025) > Potential Roles of PDE4 Inhibitors in Peptic Ulcer Treatment

Potential Roles of PDE4 Inhibitors in Peptic Ulcer Treatment

Khaled A. Abdel-Sater

For citation:


  • Abstract
  • About the Author
  • References

Abstract

Introduction. Peptic ulcer disease, a common gastrointestinal disorder, is mostly caused by Helicobacter pylori infection, non-steroidal anti-inflammatory drug usage, and lifestyle factors including alcohol use and smoking. Irsogladine, a non-specific selective PDE4 inhibitor, has demonstrated therapeutic potential in gastric ulcers by promoting mucosal healing, reducing inflammation, and enhancing antioxidant defenses. This review explores the therapeutic potential of irsogladine and PDE4B inhibitors in treating peptic ulcers. Methods. To find appropriate research for this review article, a thorough literature search was carried out utilizing electronic databases such as Google Scholar and PubMed. Keywords such as “peptic ulcer”, “Phosphodiesterase-4 inhibitors”, “irsogladine”, “cAMP” and “mucosal healing” were used in the search strategy. Only recent, English-language publications were included in the search. Conclusion. Phosphodiesterase-4 inhibitors, particularly those targeting phosphodiesterase -4B inhibitors, play a significant role in modulating immune responses, reducing oxidative stress, and supporting angiogenesis. These properties make them a promising therapeutic approach for peptic ulcer disease. Future research should focus on optimizing the selectivity of phosphodiesterase-4 inhibitors, evaluating their long-term safety, and conducting large-scale clinical trials to establish their efficacy in peptic ulcer management. 
Keywords: peptic ulcer, phosphodiesterase, cyclic adenosine monophosphate, irsogladine maleate, selective PDE4B inhibitors.

About the Author

Khaled A. Abdel-Sater 1

1 Department of Dental and Medical Sciences, Faculty of Dentistry, Mutah University, Al-Karak, Jordon

References

1. Barr M, Buckley M, O'Morain C. Review article: non-steroidal anti-inflammatory drugs and Helicobacter pylori. Aliment Pharmacol Ther 2000;14(Suppl 3):43-7. DOI: 10.1046/j.1365-2036.2000.00399.x. PMID: 11050486. 
2. Lebowa W, Skorus U, Rapacz K et al. Indications for Emergency Abdominal Surgeries in Older Patients: 7-Year Experience of a Single Centre. Indian J Surg 2021;83(1):78-84. DOI: 10.1007/s12262-020-02203-0 3. Tarnawski AS, Ahluwalia A. The Critical Role of Growth Factors in Gastric Ulcer Healing: The Cellular and Molecular Mechanisms and Potential Clinical Implications. Cells 2021;10(8):1964. DOI: 10.3390/ cells10081964 
4. Golovynska I, Beregova TV, Falalyeyeva TM et al. Peripheral N-methyl-D-aspartate receptor localization and role in gastric acid secretion regulation: immunofluorescence and pharmacological studies. Sci Rep 2018;8(1):7445. DOI: 10.1038/s41598-018-25753-6. PMID: 29749407; PMCID: PMC5945873. 
5. Bondarev AD, Attwood MM, Jonsson J et al. Recent developments of phosphodiesterase inhibitors: Clinical trials, emerging indications and novel molecules. Front Pharmacol 2022;13:1057083. DOI: 10.3389/ fphar.2022.1057083 
6. Kolb M, Crestani B, Maher TM. Phosphodiesterase 4B inhibition: a potential novel strategy for treating pulmonary fibrosis. Eur Respir Rev 2023;32(167):220206. Published 2023 Feb 21. DOI: 10.1183/ 16000617. 0206-2022 
7. Houslay MD, Schafer P, Zhang KY. Keynote review: Phosphodiesterase-4 as a therapeutic target. Drug Discovery Today 2005;10(22):1503-19. 
8. Fan T, Wang W, Wang Y et al. PDE4 inhibitors: potential protective effects in inflammation and vascular diseases. Front Pharmacol 2024;15:1407871. Published 2024 Jun 10. DOI: 10.3389/fphar.2024. 1407871 
9. Shim KN, Kim JI, Kim N et al. The efficacy and safety of irsogladine maleate in nonsteroidal anti-inflammatory drug or aspirin-induced peptic ulcer and gastritis. Korean J Intern Med 2019;34(5):1008-21. DOI: 10.3904/kjim.2017.370 
10. Blauvelt A, Langley RG, Gordon KB et al. Next Generation PDE4 Inhibitors that Selectively Target PDE4B/D Subtypes: A Narrative Review. Dermatol Ther (Heidelb) 2023;13(12):3031-42. DOI: 10.1007/ s13555-023-01054-3 
11. Herrmann FE, Hesslinger C, Wollin L, Nickolaus P. Corrigendum: BI 1015550 is a PDE4B inhibitor and a clinical drug candidate for the oral treatment of idiopathic pulmonary fibrosis. Front Pharmacol 2023;14:1219760. Published 2023 May 30. DOI: 10.3389/fphar.2023.1219760 
12. Akagi M, Amagase K, Murakami T, Takeuchi K. Irsogladine: overview of the mechanisms of mucosal protective and healing- promoting actions in the gastrointestinal tract. Curr Pharm Des 2013;19(1):106-14. DOI: 10.2174/13816128130115 
13. Kwon SC, Kim JH. Gastroprotective effects of irsogladine maleate on ethanol/hydrochloric acid induced gastric ulcers in mice. Korean J Intern Med 2021;36(1):67-75. DOI: 10.3904/kjim.2018.290 
14. Zhang X, Tajima K, Kageyama K, Kyoi T. Irsogladine maleate suppresses indomethacin-induced elevation of proinflammatory cytokines and gastric injury in rats. World J Gastroenterol 2008;14(30):4784-90. DOI: 10.3748/wjg.14.4784 
15. Kuramoto T, Umegaki E, Nouda S et al. Preventive effect of irsogladine or omeprazole on non-steroidal anti-inflammatory drug-induced esophagitis, peptic ulcers, and small intestinal lesions in humans, a prospective randomized controlled study. BMC Gastroenterol 2013;13:85. DOI: 10.1186/1471-230X-13-85 
16. Su Y, Ding J, Yang F et al. The regulatory role of PDE4B in the progression of inflammatory function study. Front Pharmacol 2022;13:982130. DOI: 10.3389/fphar.2022.982130 
17. Bondarev AD, Attwood MM, Jonsson J et al. Recent developments of phosphodiesterase inhibitors: Clinical trials, emerging indications and novel molecules. Front Pharmacol 2022;13:1057083. DOI: 10.3389/ fphar.2022.1057083

For citation: Abdel-Sater Kh.A. Potential Roles of PDE4 Inhibitors in Peptic Ulcer Treatment. Clinical review for general practice. 2025; 6 (6): 28–30 (In Russ.). DOI: 10.47407/kr2025.6.6.00626


All accepted articles publish licensed under a Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.

  • About
  • Editorial board
  • Ethics
  • For authors
  • Author fees
  • Peer review
  • Contacts

oa
crossref
анри


  Indexing

Scopus
doaj
elibrary

Address of the Editorial Office:

127055, Moscow, s/m 37

Correspondence address:

115054, Moscow, Zhukov passage, 19, fl. 2, room XI


Managing Editor:

+7 (495) 926-29-83

id@con-med.ru